-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

Benzinga·09/16/2026 12:22:34
语音播报
Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform and maintains $55 price target.